Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration

Teicoplanin-based antimicrobial therapy in Staphylococcus aureus bone and joint infection: tolerance, efficacy and experience with subcutaneous administration

Abstract Background Staphylococci represent the first etiologic agents of bone and joint infection (BJI), leading glycopeptides use, especially in case of methicillin-resistance or betalactam intolerance. Teicoplanin may represent an alternative to vancomycin because of its acceptable bone penetrati...

Full description

Bibliographic Details
Main Authors: Olivier Peeters, Tristan Ferry, Florence Ader, André Boibieux, Evelyne Braun, Anissa Bouaziz, Judith Karsenty, Emmanuel Forestier, Frédéric Laurent, Sébastien Lustig, Christian Chidiac, Florent Valour, on behalf of the Lyon BJI study group
Format: Article
Language:English
Published: BMC 2016-11-01
Series:BMC Infectious Diseases
Subjects:
Bone and joint infection
Staphylococcus aureus
Teicoplanin
Subcutanous administration
Online Access:http://link.springer.com/article/10.1186/s12879-016-1955-7

Internet

http://link.springer.com/article/10.1186/s12879-016-1955-7

Similar Items